

HAJIR DADGOSTAR, M.D., Ph.D.

The Retina Partners

16500 Ventura Blvd., Suite 250
Encino, CA 91436
Tel. 818-788-9333
Fax. 818-788-9273
www.theretinapartners.com

CLINICAL PRACTICE

- 2015 - present** **The Retina Partners** - Los Angeles, CA
Partner/Co-Founder
Physician - Vitreoretinal Surgery
- 2009 - 2014** **Valley Retina Associates Medical Group** - Encino, CA
Partner/Co-Owner
Physician - Vitreoretinal Surgery

ACADEMIC AFFILIATIONS

- 2011 - 2023** **Stein Eye Institute - UCLA** - Los Angeles, CA
Assistant Clinical Professor of Ophthalmology
- 2010 - 2023** **West Los Angeles VA Medical Center** - Los Angeles, CA
Clinical Faculty - Vitreoretinal Surgery

HOSPITAL/ASC AFFILIATIONS

- 2024 - present** **Pacific Surgery Center of Santa Monica** - Santa Monica, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2024 - present** **Saint John's Hospital Medical Center** - Santa Monica, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2017 - present** **West Hills Hospital Medical Center** - West Hills, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2015 - present** **Specialty Surgery Center** - Beverly Hills, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2013 - present** **Valley Physicians Surgery Center** - Northridge, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2011 - present** **Freedom Vision Ambulatory Surgery Center** - Encino, CA
Physician/Surgeon - Vitreoretinal Surgery
- 2009 - 2017** **Northridge Hospital Medical Center** - Northridge, CA
Physician - Vitreoretinal Surgery

EDUCATION

- 1995 - 2003** **UCLA School of Medicine - Medical Scientist Training Program -**
Los Angeles, CA
Doctor of Medicine
May 2003
- 1997 - 2001** **UCLA Molecular Biology Institute -** Los Angeles, CA
Doctor of Philosophy in Molecular Biology
April 2001
- 1991 - 1995** **University of California, Los Angeles -** Los Angeles, CA
Bachelor of Science in Psychobiology with Honors; *Summa Cum Laude*
March 1995

RESIDENCY TRAINING

- 2004 - 2007** **Jules Stein Eye Institute - UCLA -** Los Angeles, CA
Clinical Residency in Ophthalmology
- 2003 - 2004** **Univeristy of Hawaii - Internal Medicine Residency Program -**
Honolulu, HI
Clinical Internship in Internal Medicine

FELLOWSHIP TRAINING

- 2007 - 2009** **Cole Eye Institute - Cleveland Clinic Foundation -** Cleveland, OH
Clinical Fellowship in Vitreoretinal Surgery

LICENSURE AND CERTIFICATIONS

- 2009 - present** **American Board of Ophthalmology -** Diplomate (***Active***)
- 2005 - present** **Medical Board of California -** Licensed Physician (***Active***)
- 2005 - present** **US Department of Justice, DEA -** Registered Practitioner (***Active***)
- 2007 - 2011** **State Medical Board of Ohio -** Licensed Physician (***Inactive***)
- 2003 - 2004** **Hawaii DCCA, Medical Board -** Licensed Physician in Training (***Inactive***)

PROFESSIONAL ASSOCIATIONS

- 2012 - present** Los Angeles County Medical Association - *Member*
- 2010 - present** Los Angeles Society of Ophthalmology - *Member, Past President*
- 2010 - present** American Society of Retina Specialists - *Member*
- 2009 - present** California Academy of Eye Physicians and Surgeons - *Member*
- 2009 - present** The Academy of Persian American Physicians - *Member, Past President*
- 2007 - present** Society of Heed Fellows - *Fellow*
- 2004 - present** American Medical Association - *Member*
- 2004 - present** American Academy of Ophthalmology - *Fellow*
- 2003 - 2009** Association for Research in Vision and Ophthalmology - *Member*

HONORS/AWARDS

- 2009** Cole Eye Institute Fellow of the Year Award

2008	Annenberg Center Mentoring in Ophthalmology Fellows Program
2007	Fellow of the Society of Heed Fellows - Special Recognition
2007	Heed Foundation Fellowship Award
2007	Jules Stein Eye Institute Clinical Research Award
2006	Dr. Henry and Lilian Nesburn Award for Best Research Paper
2006	Pepose-Saltzman Young Investigator Award
2003	Emil Bogen Research Award
2003	California Endowment Scholar
2003	APSIH Young Scholar Award
2003	APSIH Recognition of Excellence in Medical Education
2002	Letter of Distinction - UCLA School of Medicine
2000	UCLA Dissertation Year Fellowship Award
1999	Warsaw Research Fellowship Award
1996	Letter of Distinction - UCLA School of Medicine
1995	<i>Summa Cum Laude</i> Graduate - UCLA
1994	Phi Beta Kappa National Honors Society
1992	Golden Key National Honors Society
1991	College Honors Scholar - UCLA (1991 - 1995)
1991	Dean's Honors List - UCLA (1991 - 1995)
1991	UCLA Alumni Scholar
1991	UC Regents Scholar

ACADEMIC SERVICE

2009 - 2013 **Northridge Hospital Medical Center** - Northridge, CA
Institutional review board

RESEARCH AFFILIATIONS

- 2024 - present ***Principal Investigator***
LUCIA: A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD.
The Retina Partners - Encino, CA
- 2024 - present ***Principal Investigator***
SOL-R: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration.
The Retina Partners - Encino, CA
- 2024 - present ***Principal Investigator***
DIAMOND-1: A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema.
The Retina Partners - Encino, CA
- 2024 - present ***Investigator/Certified Surgeon***
BURGUNDY: A Three-Part, Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following

Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2023 - present

Principal Investigator

KHK4951-003: A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema.

The Retina Partners - Encino, CA

2023 - present

Principal Investigator

KHK4951-002: A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2022 - present

Investigator

HONU: An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2022 - 2024

Principal Investigator

DAVIO2: A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD.

The Retina Partners - Encino, CA

2022 - 2023

Principal Investigator

OCULIS-Stage1: A Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.

The Retina Partners - Encino, CA

2022 - 2023

Principal Investigator

BEHOLD: A Phase 2, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema.

The Retina Partners - Encino, CA

2022 - present

Investigator/Certified Surgeon

ASCENT: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD.

The Retina Partners - Encino, CA

2022 - present

Investigator/Certified Surgeon

ATMOSPHERE: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD.
The Retina Partners - Encino, CA

2022 - 2024

Investigator

DREAM: OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR).
The Retina Partners - Encino, CA

2021 - present

Investigator

SHORE: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD.
The Retina Partners - Encino, CA

2021 - 2023

Principal Investigator

MYLIGHT: A 52-Week Multicenter, Randomized, Double-Masked, 2-Arm Parallel Study to Compare Efficacy, Safety and Immunogenicity Of SOK583A1 To Eylea®, Administered Intravitreally, in Patients with Neovascular Age-Related Macular Degeneration.
The Retina Partners - Encino, CA

2021 - 2022

Principal Investigator

GEMINI: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration.
The Retina Partners - Encino, CA

2021 - present

Principal Investigator

BALATON: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion.
The Retina Partners - Encino, CA

2021 - present

Principal Investigator

COMINO: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
The Retina Partners - Encino, CA

2021 - 2023

Investigator

Longitude: A Longitudinal Biomarker Study to Explore the Composition of Aqueous Humor and the Associated Multimodal Retinal Imaging in Anti-VEGF Treatment-Naïve Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, Before and After Aflibercept Treatment.
The Retina Partners - Encino, CA

- 2020 - 2023** ***Investigator***
CATALINA: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
The Retina Partners - Encino, CA
- 2020 - present** ***Investigator/Certified Surgeon***
PAVILION: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy.
The Retina Partners - Encino, CA
- 2019 - present** ***Principal Investigator***
PHOTON: A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study Of The Efficacy And Safety Of High-Dose Aflibercept In Patients With Diabetic Macular Edema.
The Retina Partners - Encino, CA
- 2019 - 2022** ***Investigator***
CANDELA: A Randomized, Single-Marked, Active-Controlled Phase 2 Study Of The Safety, Tolerability, And Efficacy Of Repeated Doses Of High-Dose Aflibercept In Patients With Neovascular Age-Related Macular Degeneration.
The Retina Partners - Encino, CA
- 2019 - 2021** ***Principal Investigator***
ALTISSIMO: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration.
The Retina Partners - Encino, CA
- 2019 - present** ***Investigator/Certified Surgeon***
PAGODA: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema.
The Retina Partners - Encino, CA
- 2019 - 2022** ***Investigator***
GALLEGO: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
The Retina Partners - Encino, CA
- 2019 - 2023** ***Principal Investigator***
TENAYA/AVONELLE-X: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and

Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2018 - 2022

Principal Investigator

XPLORE: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2018 - 2021

Principal Investigator

PANDA-1: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD).

The Retina Partners - Encino, CA

2018 - 2023

Investigator

RHINE/RHONE-X: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema.

The Retina Partners - Encino, CA

2018 - 2021

Investigator

DERBY: A Phase II, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study To Compare The Efficacy And Safety Of Intravitreal APL-2 Therapy With Sham Injections In Patients With Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration.

The Retina Partners - Encino, CA

2018 - 2021

Investigator/Certified Surgeon

ARCHWAY: A phase III study to evaluate the Port Delivery System implant with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration.

The Retina Partners - Encino, CA

2018 - present

Investigator/Certified Surgeon

PORTAL: Extension study for the Port Delivery System with ranibizumab.

The Retina Partners - Encino, CA

2016 - 2017

Principal Investigator

ONYX: A phase II study evaluating the efficacy, safety and tolerability of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.

The Retina Partners - Encino, CA

2015 - 2019

Principal Investigator

CEDAR: A phase III study evaluating the safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration.

The Retina Partners - Encino, CA

- 2015 - 2017** ***Investigator***
AVENUE: A proof-of-concept study of RG7716 in participants with choroidal neovascularization secondary to age-related macular degeneration.
The Retina Partners - Encino, CA
- 2015 - 2018** ***Investigator/Certified Surgeon***
LADDER: A phase II study of the efficacy and safety of the Ranibizumab Port Delivery System for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
The Retina Partners - Encino, CA
- 2015 - 2017** ***Investigator***
GX29455: A phase II study of Lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy.
The Retina Partners - Encino, CA
- 2014 - 2016** ***Investigator***
ORBIT: Post-market evaluation of the safety and efficacy of ocriplasmin intravitreal injection in the treatment of symptomatic vitreomacular adhesion.
The Retina Partners - Encino, CA
- 2014 - 2017** ***Investigator***
CentraSight PAS-01: Post-market evaluation of the outcomes and efficacy of an implantable miniature telescope for patients with advanced bilateral vision loss secondary to macular degeneration.
The Retina Partners - Encino, CA
- 2013 - 2015** ***Adjunct Study Site Faculty***
Alcon C-12-071: Nepafenac once daily for macular edema.
The Retina Partners - Encino, CA
- 2007 - 2009** ***Principal Investigator***
LNRP: Evaluation of the association between macular lesion morphology in age-related macular degeneration and the response to VEGF-inhibitor therapy.
Cole Eye Institute - Cleveland, OH
- 2009** ***Investigator***
VIEW1: A phase III, double-masked, randomized study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
Cole Eye Institute - Cleveland, OH
- 2007 - 2009** ***Investigator***
DENALI: A double-masked, randomized study evaluating combination verteporfin/ranibizumab therapy for exudative age-related macular degeneration.
Cole Eye Institute - Cleveland, OH
- 2007 - 2009** ***Investigator***

CRUISE: A study of the efficacy and safety of ranibizumab injection in patients with macular edema secondary to central retinal vein occlusion.
Cole Eye Institute - Cleveland, OH

2007 - 2009

Certified Reader

Digital Angiography Reading Center/Digital OCT Reading Center
Cole Eye Institute - Cleveland, OH

2007 - 2008

Investigator

AART: Anecortave Acetate Risk Reduction Trial for dry age-related macular degeneration
Cole Eye Institute - Cleveland, OH

2002 - 2007

Physician Researcher

Study of retinal blood flow abnormalities in HIV-positive individuals.
Jules Stein Eye Institute - Los Angeles, CA

1999 - 2000

Academic Collaborator

Global expression analysis in activated B lymphocytes.
Project proposal selected for collaboration in a nation-wide competitive application process.
Affymetrix, Inc., Academic User Center - Santa Clara, CA

1997 - 2001

Graduate Student Researcher

Molecular dissection of inflammatory intracellular signal transduction pathways.
UCLA Molecular Biology Institute - Los Angeles, CA

1996

Graduate Student Researcher

Study of CNS myelination through an immunological approach using antibodies that block myelin synthesis *in vitro*.
UCLA School of Medicine - Los Angeles, CA

1995

Graduate Student Researcher

Cloning of a gene involved in neuronal connectivity in *Drosophila*.
UCLA School of Medicine Department of Biological Chemistry/Howard Hughes Medical Institute - Los Angeles, CA

1993 - 1995

Undergraduate Student Researcher

Characterization of a polymorphic dinucleotide repeat within the human mu opioid receptor gene.
UCLA School of Medicine - Los Angeles, CA

REVIEW ARTICLES

Dadgostar, H. and Kaiser, P. K. 2009. siRNA Therapeutics for Age-related Macular Degeneration: Promises and Pitfalls. *Exp Rev Ophthalmol.* 4(5): 525-535.

Dadgostar, H. and Kaiser, P. K. 2009. Combination Therapies for Exudative AMD: A Look at Current Treatment Regimens and a Review of the Evidence. *Rev Ophthalmol.* 16(5): 72-78.

Dadgostar, H. and Waheed, N. 2008. The Evolving Role of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Neovascular Age-related Macular Degeneration. *Eye*. 22(6): 761-767.

Dadgostar, H. 2008. Safety, Efficacy, and Dosing Schedules for Ranibizumab in Exudative Age-related Macular Degeneration: A Comparative Review of Data from Multiple Clinical Trials. *The Ophthalmology Report*. 2(3): 13-19.

RESEARCH ARTICLES

Eichenbaum DA, Freeman WR, Chang MA, Brooks L, Chaudhry N, **Dadgostar H**, McCannel CA, Michels M, Mittra RA, Wolfe JD, Beindl VC, Jaycock P, Bobbala A, Gune S, Spicer G, Callaway N. 2025. Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development. *Ophthalmol Retina*. 9(2):127-143.

Ventura, A. A., Grant, L. W., **Dadgostar, H.**, Lewis, H. 2011. Intravitreal Injection of Ranibizumab for Foveal-Macular Pattern Dystrophy: Case Report. *Arq Bras Oftalmol*. 74(4): 289-291.

Sachdeva, R., **Dadgostar, H.**, Kaiser, P. K., Sears, J. E., Singh, A. D. 2010. Verteporfin Photodynamic Therapy of Six Eyes with Retinal Capillary Haemangioma. *Acta Ophthalmol*. 88(8): e334-340.

Dadgostar, H., Ventura, A. A. C. M., Chung, J., Sharma, S., Kaiser, P. K. 2009. Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration. *Ophthalmology* 116(9): 1740-1747.

Dadgostar, H., Holland, G. N., Huang, X., Tufail, A., Kim, A., Fisher, T. C., Cumberland, W. G., Meiselman, H. J., Benjamin, A. and Bartsch, D.-U. 2006. Hemorheologic Abnormalities Associated with HIV Infection: In Vivo Assessment of Retinal microvascular Blood Flow. *Invest Ophthalmol Vis Sci*. 47(9): 3933-3938.

Kim, A., * **Dadgostar, H.**,* Holland, G. N., Wenby, R., Yu, F., Terry, B. G. and Meiselman, H. J. 2006. Hemorheologic Abnormalities Associated with HIV Infection: Altered Erythrocyte Aggregation and Deformability. *Invest Ophthalmol Vis Sci*. 47(9): 3927-3932.

*These authors contributed equally to this work

Dadgostar, H.,* Doyle, S. E.,* Shahangian, A.,* Garcia, D. E. and Cheng, G. 2003. T3JAM, a Novel Protein that Specifically Interacts with TRAF3 and Promotes the Activation of JNK(1). *FEBS Lett*. 553(3): 403-407.

*These authors contributed equally to this work

Doyle, S. E., Vaidya, S. A., O'Connell, R., **Dadgostar, H.**, Dempsey, P. W., Wu, T., Rao, G., Sun, R., Haberland, M. E., Modlin, R. L. and Cheng, G. 2002. IRF3 Mediates a TLR3/TLR4-Specific Anti-Viral Gene Program. *Immunity*. 17(3): 251-263.

Dadgostar, H., Zarnegar, B., Hoffmann, A., Qin, X.-F., Truong, U., Rao, G., Baltimore, D. and Cheng, G. 2002. Cooperation of Multiple Signaling Pathways in CD40-regulated Gene Expression in B Lymphocytes. *Proc. Natl. Acad. Sci. USA*. 99: 1497-1502.

Dadgostar, H. and Cheng, G. 2000. Membrane Localization of TRAF 3 Enables JNK Activation. *J Biol Chem.* 275(4): 2539-2544.

Lee, H.,* **Dadgostar, H.**,* Cheng, Q., Shu, J., and Cheng, G. 1999. NF- κ B-Mediated Up-Regulation of Bcl-x and Bfl-1/A1 is Required for CD40 Survival Signaling in B Lymphocytes. *Proc. Natl. Acad. Sci. USA.* 96: 9136-9141.

*These authors contributed equally to this work

Dadgostar, H. and Cheng, G. 1998. An Intact Zinc Ring Finger is Required for TRAF-mediated NF- κ B Activation but is Dispensable for JNK Signaling. *J Biol Chem.* 273(38): 24775-24780.

ABSTRACTS

Dadgostar, H., Ventura, A. A. C. M., Sharma, S., Chung, J., Kaiser, P. K. 2008. OCT Lesion Morphology and the Response of Exudative AMD to Ranibizumab. American Academy of Ophthalmology (Atlanta, GA).

Dadgostar, H., Ventura, A. A. C. M., Sharma, S., Chung, J., Kaiser, P. K. 2008. Early Lesion Morphology and Anatomic versus Functional Treatment Response to Ranibizumab Therapy for Exudative Age-Related Macular Degeneration. American Society of Retina Specialists (Maui, HI).

Dadgostar, H., Silveira, C., Jones, J. L., Lee, G., Muccioli, C., Belfort, R., Holland, G. N. 2008. Risk Factors for Ocular Toxoplasmosis Among Individuals Recently Infected by *Toxoplasma gondii* in Southern Brazil. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).

Dadgostar, H., Holland, G. N., Huang, X., Tufail, A., Kim, A., Fisher, T. C., Cumberland, W. G., Meiselman, H. J., Benjamin, A. and Bartsch, D.-U. 2006. A Relationship Between Altered *in vivo* Retinal Microvascular Blood Flow and Leukocyte Rigidity in HIV-Infected Individuals. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).

Kim, A., **Dadgostar, H.**, Holland, G. N., Wenby, R. B., Yu, F. and Meiselman, H. J. 2003. Hemorheologic Abnormalities in HIV-Infected Individuals with CD4+ T-lymphocyte Counts >200/ μ L. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).

Vaidya, S. A., Doyle, S. E., O'Connell, R., **Dadgostar, H.**, Dempsey, P. W., Wu, T., Rao, G., Sun, R., Haberland, M. E., Modlin, R. L. and Cheng, G. 2003. The Role of IRF3 in TLR-Specific Gene Expression in Macrophages. Keystone Symposia (Taos, NM).

Dadgostar, H., Zarnegar, B. and Cheng, G. 2000. A Global Analysis of CD40- and LPS-Mediated Gene Regulation in B Lymphocytes. National MD/PhD Student Conference (Aspen, CO).

Dadgostar, H. and Cheng, G. 1999. The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling. Keystone Symposia (Keystone, CO).

Keith, D., Evans, C., Tian, J., Wen, C., Tran, T., **Dadgostar, H.**, Phan, T., Anton, B., Magenzo, K., Zaki, P., Maung, T., and Kaufman, D. 1994. Characterization of a Mouse Mu Opioid Receptor. International Narcotics Research Conference (Cape Cod, MA).

Kaufman, D. L., Selleri, L., Ting, G. S. P., Newman, D., Keith, D., Phan, T., Tian, J., Tran, T., **Dadgostar, H.**, Giovannini, M., Evans, C. J., and Barchas, J. D. 1993. Characterization of the Human Delta Opioid Receptor Gene. Society for Neuroscience (Washington D.C.).

DOCTORAL DISSERTATION

Dadgostar, H. A Multi-Level Dissection of CD40-Activated Intracellular Signal Transduction Pathways. Copyright by H. Dadgostar. 2001.

BOOK CHAPTERS

Steinle, N. C., **Dadgostar, H.**, and Sears, J. E. Ocular Trauma. In *Ophthalmic Ultrasonography*. 2012. Eds. Singh, A. D. and Hayden, B. C. Elsevier Saunders.

Dadgostar, H., Ventura, A. A. C. M., and Hayden, B. C. Posterior Segment Trauma. In *Ultrasound Clinics: Ophthalmic Ultrasound*. 3(2): 267-272. 2008. Eds. Singh, A. D., Hayden, B. C. and Pavlin, C. J. Elsevier Science.

Dadgostar, H. and Kaiser, P. K. PDT and Combination Treatment with PDT and AMD. In *Macular Degeneration: State of the Art*. 2008. Remedica Publishing, London.

Dadgostar, H. and Kaiser, P. K. Anecortave Acetate. In *Retinal Pharmacotherapy, 1st Edition*. 2008. Eds. Nguyen, Q. D., Rodrigues, E. B., Farah, M. E., and Mieler, W. F. Elsevier Science.

Dadgostar, H. and Singh, A. D. Retinal Vascular Tumors. In *Encyclopedia of Ophthalmology: Ophthalmic Pathology and Ocular Tumors*. 2008. Eds. Schmidt-Erfurth, U., Mieler, W. F., Williams, G. A. Springer Verlag.

Dadgostar, H. and Kaiser, P. K. How Should I Follow Diabetic Macular Edema and When Does it Require Treatment? In *Curbside Consultation in Retina*. 2008. Eds. Fekrat, S., Moshfeghi, D., Elliott, D. and Haller, J. Slack, Inc.

INVITED LECTURE PRESENTATIONS

October 14, 2017—"The Role of Inflammation in Age-Related Macular Degeneration"; The Academy of Persian American Physicians 22nd Annual Scientific Meeting (Ojai, CA).

November 10, 2016—"Novel Therapies for Neovascular and Non-Neovascular Age-Related Macular Degeneration"; American Academy of Optometry, Retina Special Interest Group, Annual Meeting 2016 (Anaheim, CA).

November 10, 2016—"Treatment Strategies in Medical Retina: Case Discussions"; American Academy of Optometry, Annual Meeting 2016 (Anaheim, CA).

December 5, 2015—"Current and Emerging Treatments in Medical Retina"; Optometric Retina Society, Retina Update 2015 (Anaheim, CA).

November 4, 2014—"Diabetic Retinopathy and Macular Edema"; Strategies to Enhance Eyesight in Patients with Diabetes, Special Symposium (Newport Beach, CA).

October 14, 2012—"Antibiotic Prophylaxis for Intravitreal Injections"; The Academy of Persian American Physicians 17th Annual Scientific Meeting (Indian Wells, CA).

March 20, 2011—"Practical Pearls in OCT Interpretation"; San Fernando Valley Optometric Society CE Program Guest Speaker (Studio City, CA).

March 19, 2011—"Differential Treatment Effects in a Common Setting: Avastin vs. Lucentis"; Combined Meeting of the Western Retina Study Club and Los Angeles Imaging Conference for Retina Specialists (Los Angeles, CA).

October 10, 2010—"Age-Related Macular Degeneration: Update"; The Academy of Persian American Physicians 15th Annual Scientific Meeting (La Jolla, CA).

January 12, 2010—"Diabetic Eye Disease"; Beverly Hills Iranian American Doctors Association (Beverly Hills, CA).

June 19, 2009—"As Needed' Ranibizumab Monotherapy in Neovascular AMD: An Analysis of Variables Related to Visual Outcomes"; Cole Eye Institute Research and Alumni Program (Cleveland, OH).

June 13, 2008—"Morphologic Analysis of Macular Lesion Changes in OCT-guided Ranibizumab Monotherapy for Exudative AMD"; Cole Eye Institute Research and Alumni Program (Cleveland, OH).

May 18, 2007—"Risk Factors for Ocular Toxoplasmosis among Individuals Recently Infected by *Toxoplasma gondii* in southern Brazil"; Jules Stein Eye Institute Clinical Research Seminar (UCLA).

May 21, 2005—"Hemorheologic Abnormalities in HIV-Infected Individuals"; Jules Stein Eye Institute Clinical Research Seminar (UCLA).

June 18, 2001—"Overlapping and Stimulus-Specific Global Activation Responses of Resting B Cells to CD40L and LPS"; CalTech-UCLA Joint Seminar on Signaling and Gene Expression (UCLA).

October 3, 2000—"Use of High-Density DNA Microarrays for a Global-Scale Analysis of CD40 Ligand- and Lipopolysaccharide-Mediated Activation of B Cells"; Access Gene Expression Affinity Group Seminar Series (UCLA).

September 18, 2000—"Overlapping and Stimulus-Specific Global Activation Responses of Resting B Cells to CD40L and LPS"; The Institute for Pure and Applied Mathematics (UCLA).

September 8, 2000—"Use of High-Density DNA Microarrays for a Global-Scale Analysis of CD40 Ligand- and Lipopolysaccharide-Mediated Activation of B Cells"; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).

June 28, 2000—"Dissecting Differential B Cell Activation Responses to CD40 Ligand and LPS through Global Gene Expression Analysis"; UCLA Dept. of Microbiology and Molecular Genetics Annual Warsaw Scholars' Luncheon (UCLA).

November 12, 1998—"An Intact Zinc Ring Finger is Required for TRAF-mediated NF- κ B Activation but is Dispensable for JNK Signaling"; Jonsson Comprehensive Cancer Center Seminar Series (UCLA).

October 24, 1998—"An Intact Zinc Ring Finger is Required for TRAF-mediated NF- κ B Activation but is Dispensable for JNK Signaling"; UCLA Molecular Biology Institute Annual Retreat (Lake Arrowhead, CA).

September 12, 1998—"Distinct Structural Requirements for TRAF-mediated NF- κ B Activation vs. JNK Activation"; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).

POSTER PRESENTATIONS

November 8, 2008—"OCT Lesion Morphology and the Response of Exudative AMD to Ranibizumab"; American Academy of Ophthalmology (Atlanta, GA).

October 12, 2008—"Early Lesion Morphology and Anatomic versus Functional Treatment Response to Ranibizumab Therapy for Exudative Age-Related Macular Degeneration"; American Society of Retina Specialists (Maui, HI).

May 1, 2008—"Risk Factors for Ocular Toxoplasmosis Among Individuals Recently Infected by *Toxoplasma gondii* in Southern Brazil"; Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).

May 2, 2006—"A Relationship Between Altered *in vivo* Retinal Microvascular Blood Flow and Leukocyte Rigidity in HIV-Infected Individuals"; Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).

March 21, 2003—"T2-2, A Novel TRAF3-Interacting Protein Involved in JNK Signaling", (David Geffen School of Medicine Poster Day (UCLA).

April 11, 2001—"Cooperation of Multiple Signaling Pathways in CD40-regulated Gene Expression in B Lymphocytes", UCLA Medical Scientist Training Program Poster Day (UCLA).

July 15, 2000—"A Global Analysis of CD40- and LPS-Mediated Gene Regulation in B Lymphocytes"; National MD/PhD Student Conference (Aspen, CO).

November 5, 1999—"Multiple Approaches to the Systematic Identification of CD40-regulated Genes", "The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling"; UCLA Jonsson Comprehensive Cancer Center Symposium (UCLA).

September 17, 1999—"Multiple Approaches to the Systematic Identification of CD40-regulated Genes"; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).

May 10, 1999—"The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling"; UCLA Signal Transduction Symposium (UCLA).

April 12, 1999—"The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling"; Keystone Symposia: Specificity in Signal Transduction (Keystone, CO).